Analysis of Prices of Six Drug Classes for Cancer for U.S Including Platinum Drugs, Hormonal Agents, Antimetabolites and Monoclonal Antibodies

Research and Markets (http://www.researchandmarkets.com/reports/c43165) has announced the addition of Cancer Therapies—Is the United States Always the Most Expensive Market? to their offering.

Dublin (PRWEB) October 10, 2006 -- Research and Markets (http://www.researchandmarkets.com/reports/c43165) has announced the addition of Cancer Therapies—Is the United States Always the Most Expensive Market? to their offering.

The cost of innovative cancer drugs is an increasingly controversial issue. Strict price controls in many countries limit the prices that manufacturers can charge for medicines, whereas the United States’ lenient drug pricing system allows manufacturers much greater latitude to determine launch prices. However, pharmaceutical companies in all countries will need to adapt to a changing pricing environment for oncology drugs.

Get the Answers You Need to Shape Your Strategy
Concern is growing over the rising costs of cancer therapies, particularly in the United States, which has the highest drug prices overall. Have drug manufactures responded to this growing concern? Is government intervention necessary to regulate prices?

Historically, the European hospital sector allowed free pricing of drugs, even in the most heavily regulated markets. But there is a growing trend to control hospital spending on medicines. What pricing controls are being proposed and how will they affect drug pricing in European markets?
Drugs typically do not reach the Japanese market until several years after their launch in the other major pharmaceutical markets. However, Japan recently initiated measures to accelerate the launch of innovative cancer therapies. How will these measures affect future drug pricing and pricing controls in Japan?

Scope
National pricing trends: United States, France, Germany, Italy, Spain, United Kingdom, Japan

Analysis of prices of six drug classes: platinum drugs, hormonal agents, taxanes, antimetabolites, monoclonal antibodies, and small-molecule tyrosine kinase inhibitors

Outlook and implications for manufacturers: how these trends impact drug manufactures in each market under study

Products Mentioned:
-   Alemtuzumab
-   Anastrozole
-   Bevacizumab
-   Bicalutamide
-   Capecitabine
-   Carboplatin
-   Cetuximab
-   Cisplatin
-   Docetaxel
-   Erlotinib
-   Gefi tinib
-   Gemcitabine
-   Goserelin
-   Imatinib
-   Leuprolide
-   Oxaliplatin
-   Paclitaxel
-   Paclitaxel (modified)
-   Panitumumab
-   Rituximab
-   Trastuzumab

The Companies mentioned inside this report include:
- Abraxis Bioscience
- Amgen
- AstraZeneca
- Berlex Labs
- Biogen Idec
- Bristol-Myers Squibb
- Eli Lilly
- Genentech
- ImClone Systems
- Merck KGaA
- Novartis
- Roche
- Sanofi -Aventis
- Schering AG
- TAP Pharmaceutical Products

For more information visit http://www.researchandmarkets.com/reports/c43165

Source: Decision Resources

Laura Wood
Senior Manager
Research and Markets
Fax: +353 1 684 99 77

###